- Home
- RCUS vs CLMT Comparison
RCUS vs CLMT Comparison
Compare RCUS & CLMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCUS
- CLMT
- Stock Information
- Founded
- RCUS 2015
- CLMT 1916
- Country
- RCUS United States
- CLMT United States
- Employees
- RCUS N/A
- CLMT N/A
- Industry
- RCUS Biotechnology: Pharmaceutical Preparations
- CLMT Oil & Gas Production
- Sector
- RCUS Health Care
- CLMT Energy
- Exchange
- RCUS Nasdaq
- CLMT Nasdaq
- Market Cap
- RCUS 1.4B
- CLMT N/A
- IPO Year
- RCUS 2018
- CLMT 2006
- Fundamental
- Price
- RCUS $13.81
- CLMT $18.96
- Analyst Decision
- RCUS Buy
- CLMT Strong Buy
- Analyst Count
- RCUS 12
- CLMT 4
- Target Price
- RCUS $34.50
- CLMT $25.75
- AVG Volume (30 Days)
- RCUS 626.1K
- CLMT 874.4K
- Earning Date
- RCUS 02-19-2025
- CLMT 02-21-2025
- Dividend Yield
- RCUS N/A
- CLMT N/A
- EPS Growth
- RCUS N/A
- CLMT N/A
- EPS
- RCUS N/A
- CLMT N/A
- Revenue
- RCUS $263,000,000.00
- CLMT $4,216,399,999.00
- Revenue This Year
- RCUS $127.65
- CLMT N/A
- Revenue Next Year
- RCUS N/A
- CLMT N/A
- P/E Ratio
- RCUS N/A
- CLMT N/A
- Revenue Growth
- RCUS 119.17
- CLMT 0.30
- 52 Week Low
- RCUS $13.51
- CLMT $9.97
- 52 Week High
- RCUS $20.31
- CLMT $25.29
- Technical
- Relative Strength Index (RSI)
- RCUS 33.05
- CLMT 37.69
- Support Level
- RCUS $13.51
- CLMT $20.61
- Resistance Level
- RCUS $15.62
- CLMT $23.20
- Average True Range (ATR)
- RCUS 0.60
- CLMT 1.34
- MACD
- RCUS -0.16
- CLMT -0.14
- Stochastic Oscillator
- RCUS 11.67
- CLMT 2.24
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.